A phase II study from 2015 showed that PC patients with previously treated disease achieved better OS with the combination of GVAX with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) compared with historical OS achieved with chemotherapy alone. This evidence concerns the gene MSLN and pachyonychia congenita.